Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: Final results of a prospective long-term study (MARPLE Study)

Journal of Hypertension

Volumn 24, Issue 3, 2006, Pages 541-548

  Schrader, Joachim ^a   Lüders, Stephan ^a   Kulschewski, Anke ^a   Hammersen, Frank ^a   Züchner, Christel ^a   Venneklaas, Ulla ^a   Schrandt, Günter ^a   Schnieders, Marion ^b   Rangoonwala, Badrudin ^c   Berger, Jürgen ^d   Dominiak, Peter ^e   Zidek, Walter ^f  

^a ST JOSEFS HOSPITAL   (Germany)

^b Institute for Hypertension and Cardiovascular Research   (Germany)

^c Hofheim ^*  (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY OF LÜBECK   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Alpha 1 microglobulin; Ambulatory blood pressure monitoring; Hypertension; Microalbuminuria; Ramipril; Tubular proteinuria

Indexed keywords

ALBUMIN; ALPHA 1 MICROGLOBULIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RAMIPRIL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; HUMAN; KIDNEY TUBULE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MORBIDITY; MORTALITY; MULTICENTER STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINALYSIS; URINARY EXCRETION;

EID: 32944464800     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000209991.48928.c4     Document Type: Article

References (34)

1. American Diabetes Asssociation. Clinical practice recommendation 2002. Diabetes Care 2002: 25 (Suppl 1):S1-S147.
2. Cohn JN, Quyyumi AA, Hollenberg NK, Jamerson KA. Surrogate markers for cardiovascular disease. Functional markers. Circulation 2004; 109 (Suppl IV):IV31-IV46.
3. Mogensen CE, Chachati A, Christensen C-K, Close CF, Deckert T, Hommel E, et al. Microalbuminuria, an early marker of renal involvement in diabetes. Uremia Invest 1985; 86:85-95.
4. Bigazzi R, Bianchi S, Nenri R, Baldari D, Baldari G, Campese VM. Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuria. J Hum Hypertens 1995; 9:827-833.
5. Jensen JS, Feldt-Rasmussen B, Borch-Johnsen K, Clausen P, Appleyard M, Jensen G. Microalbuminuria in arterial hypertension: relation to cardiovascular disease and antihypertensive agents. J Hum Hypertens 1997; 11:727-732.
6. Weir MR. Microalbuminuria in type 2 diabetics: an important, overlooked cardiovascular risk factor. J Clin Hypertens (Greenwich) 2004; 6:134-141.
7. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in nondiabetic subjects. Islington Diabetes Survey. Lancet 1988; 2:530-533.
8. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as predictor of increased mortality in elderly people. BMJ 1990; 300:297-300.
9. Gerstein HC, Mann JF, Pogue J, Dinneen SF, Halle JP, Hoogwerf B, et al., for the HOPE Study investigators. Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation study. Diabetes Care 2000; 23 (Suppl 2):B35-B39.
10. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997; 157:1413-1418.
11. Parving HH, Mogensen CE, Jensen HA, Evrin PE. Increased urinary albumin-excretion rate in benign essential hypertension. Lancet 1974; 1:1190-1192.
12. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998; 16:1325-1333.
13. Haffner SM, Stern MP, Gruber MKK, Hazuda HP, Mitchell BD, Patterson JK. Microalbuminuria: potential marker for increased cardiovascular risk factor in non-diabetic subjects? Arteriosclerosis 1990; 5:727-731.
14. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
15. Kordonouri O, Hartmann R, Muller C, Danne T, Weber B. Predictive value of tubular markers for the development of microalbuminuria in adolescents with diabetes. Horm Res 1998; 50 (Suppl 1):23-27.
16. Tylicki L, Manitius J, Lysiak-Szydlowska W, Rutkowski B. Tubular injury: the first symptom of hypertensive kidney involvement? Med Sci Monit 2003; 9:CR135-CR141.
17. Schultz CJ, Dalton RN, Neil HA, Konopelska-Bahu T, Dunger DB, Oxford Regional Prospective Study Group. Markers of renal tubular dysfunction measured annually do not predict risk of microalbuminuria in the first few years after diagnosis of type I diabetes. Diabetologia 2001; 44:224-229.
18. Guidi E, Giglioni A, Cozzi MG, Minetti EE. Which urinary proteins are decreased after angiotensin converting-enzyme inhibition? Renal Fail 1998; 20:243-248.
19. Hervey GR. Determination of creatinine by the Jaffe reaction. Nature 1953; 171:1125.
20. Dati F, Lammers M. Immunochemical methods for determination of urinary proteins (albumin and α1-microglobulin) in kidney disease. J Int Fed Clin Chem 1989; 1:68-70.
21. Lapin A, Gabl F, Kopsa H. Diagnostic use of an analysis of urinary proteins by a practicable sodium dodecyl sulfate-electrophoresis method and rapid two-dimensional electrophoresis. Electrophoresis 1989; 10:589-595.
22. Romundstad S, Holmen J, Hallan H, Kvenild K, Ellekjaer H. Microalbuminuria and all-cause mortality in treated hypertensive individuals: does sex matter? The Nord-Trondelag Health Study (HUNT), Norway. Circulation 2003; 108:2783-2789.
23. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982; 1:1430-1432.
24. Redon J, Rodicio JL. Microalbuminuria in type 1 diabetes mellitus. J Hypertens 2004; 22:1425-1428.
25. Redon J, Williams B. Microalbuminuria in essential hypertension. Redefining the threshold. J Hypertens 2002; 20:353-355.
26. Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE, Wareham NJ. A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a british population. The EPIC-Norfolk Study. Am J Epidemiol 2004; 159:284-293.
27. Bianchi S, Bigazzi R, Amoroso A, Campese SV. Silent ischemia is more prevalent among hypertensive patients with microalbuminuria and salt sensitivity. J Hum Hypertens 2003; 17:13-20.
28. Ravera M, Ratto E, Vettoretti S, Viazzi F, Leoncini G, Parodi D, et al. Microalbuminuria and subclinical cerebrovascular damage in essential hypertension. J Nephrol 2002; 15:519-524.
29. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients. Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 2005; 45:198-202.
30. Pontremoli R, Sofia A, Ravera M, Nicolella C, Viazzi F, Tirotta A, et al. Prevalence and clinical correlates of microalbuminuria in essential hypertension. The MAGIC study. Hypertension 1997; 30:1135-1143.
31. Palatini P, Graniero GR, Mormino P, Mattarei M, Sanzuol F, Cignacco GB, et al., on behalf of the HARVEST Study Group. Prevalence and clinical correlates of microalbuminuria in stage-I hypertension. Results from the Hypertension and Ambulatory Recording Venetia Study (HARVEST study). Am J Hyertens 1996; 9:334-341.
32. Bigazzi R, Bianchi S, Campese VM, Baldari G. Prevalence of microalbuminuria in a large population of patients with mild to moderate essential hypertension. Nephron 1992; 61:94-97.
33. Tylicki L, Manitus J, Lysiak-Szydlowska W, Rutkowski B. Tubular injury: the first symptom of hypertensive kidney involvement? Med Sci Monit 2003; 9:CR187-CR193.
34. Marin P, Julve R, Chaves FJ, Giner V, Pascual JM, Armengod ME, et al. Polymorphisms of the angiotensinogen gene and the outcome of microalbuminuria in essential hypertension: a 3-year follow-up study. J Hum Hypertens 2004; 18:25-31.